[ Price : $8.95]
CeleCor Therapeutics says it has submitted an NDA for Disaggpro (zalunfiban), an investigational treatment for ST-segment elevatio...[ Price : $8.95]
The FY2025 FDA Report on the State of Pharmaceutical Quality shows increased quality assurance inspections over FY 2024.[ Price : $8.95]
A newly published commentary in the journal Stem Cell Research & Therapy says FDAs efforts to reduce reliance on animal testing is...[ Price : $8.95]
Two stakeholders ask for greater specificity in an FDA draft guidance on establishing impurity specifications for antibiotics.[ Price : $8.95]
Three stakeholders comment on an FDA request for information on AI-enabled optimization of early-stage clinical trials.[ Price : $8.95]
Speaking at a BIO International Convention FDA Town Hall, several agency executives cite increases in hiring and decreases in attr...[ Price : $8.95]
A new analysis published in JAMA Psychiatry raises fresh questions about how FDA evaluates drug efficacy when clinical trial resul...[ Price : $8.95]
FDA grants Pfizer expanded approval for Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy...